Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 9/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL594625 | 0.91 | APP (0.54) | APPMTNR1AMTNR1BFAAHCHRNB2 | |
| SCHEMBL7455570 | 0.87 | APP (0.60) | APPMTNR1AMTNR1BFAAHCHRNB2 | |
| SCHEMBL7239002 | 0.84 | APP (0.54) | APPMTNR1AMTNR1BFAAHCHRNB2 | |
| SCHEMBL7022072 | 0.84 | FAAH (0.56) | APPMTNR1AMTNR1BFAAHKMT2A | |
| SCHEMBL21835116 | 0.83 | APP (0.50) | APPMTNR1AMTNR1BFAAHCHRNB2 | |
| SCHEMBL30879982 | 0.83 | APP (0.50) | APPMTNR1AMTNR1BFAAHCHRNB2 | |
| SCHEMBL5957100 | 0.83 | MTNR1A (0.53) | APPMTNR1AMTNR1BFAAHCHRNB2 | |
| SCHEMBL10660855 | 0.83 | TSHR (0.58) | APPMTNR1AMTNR1BFAAHTSHR | |
| SCHEMBL15965349 | 0.83 | APP (0.53) | APPMTNR1AMTNR1BFAAHCHRNB2 | |
| SCHEMBL1428483 | 0.83 | KDM4E (0.56) | APPMTNR1AMTNR1BCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067928-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067928-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067928-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2376085-B1 | COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-02-26 | — | — | EP | disclosed |
| EP-2376085-B1 | COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20140005190-A1 | COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-8518970-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518970-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518970-B2 | Compounds and methods of use | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2012-07-19 | — | — | US | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2376085-A1 | COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010080478-A1 | COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080478-A1 | COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-0044940-B1 | AMINO-DESOXY-1.4;3.6-DIANHYDRO-HEXITE NITRATES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | Dr. Willmar Schwabe GmbH & Co. (DE) | 1984-09-19 | — | — | EP | disclosed |
| US-4363805-A | TREATMENT OF CORONARY DISEASE | FIRMA WILLMAR SCHWABE (DE) | 1982-12-14 | — | — | US | disclosed |
| EP-0044940-A1 | Amino-desoxy-1.4;3.6-dianhydro-hexite nitrates, processes for their preparation and pharmaceutical compositions | Dr. Willmar Schwabe GmbH & Co. (DE) | 1982-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005190-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | APP 1543/4885MTNR1A 1340/4885MTNR1B 362/4885 |
| US-20100190782-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | APP 1543/4885MTNR1A 1340/4885MTNR1B 362/4885 |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | APP 1543/4885MTNR1A 1340/4885MTNR1B 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.